May 26, 2022
Loading...
You are here:  Home  >  'Amgen'  -  Page 40
Latest

Our view: Amgen’s smart moves keep it poised to grow

By   /  Friday, February 10th, 2017  /  Editorials, Latest news, Opinion  /  Comments Off on Our view: Amgen’s smart moves keep it poised to grow

From its perch in Thousand Oaks, Amgen continues to be one of the savvier companies in the biopharma space when it comes to navigating drug policy and drug pricing. It continues to win the battle to keep copycat biosimilars from eroding its core franchises while gaining approval for new drugs – the latest is for Read More →

Latest

Drug sales for biotech giant Amgen boost bottom line

By   /  Friday, February 10th, 2017  /  Earnings, Health Care & Life Science, left, Technology, Tri-County Public Companies  /  Comments Off on Drug sales for biotech giant Amgen boost bottom line

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease

By   /  Tuesday, February 7th, 2017  /  Health Care & Life Science, Latest news  /  Comments Off on FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease

The U.S. Food and Drug Administration approved Amgen’s Parsabiv drug to treat patients with chronic kidney disease, the company announced on Feb. 7. The Thousand Oaks-based biotech company’s Parsabiv is the first therapy approved for the treatment of secondary hyperparathyroidism for patients on hemodialysis in 12 years, Amgen said. “We are excited about today’s approval Read More →

Latest

Amgen funds STEM program for Girl Scouts

By   /  Friday, February 3rd, 2017  /  Health Care & Life Science, Higher Education, Latest news, Nonprofits  /  Comments Off on Amgen funds STEM program for Girl Scouts

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen beats analyst estimates for fourth quarter revenue

By   /  Thursday, February 2nd, 2017  /  Earnings, Health Care & Life Science, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Amgen beats analyst estimates for fourth quarter revenue

Thousand Oaks-based biotech giant Amgen reported revenue of $6 billion in the fourth quarter of 2016, besting analyst estimates of $5.74 billion and increasing 8 percent from the fourth quarter of 2015. The world’s largest biotech drug maker posted total revenues of $23 billion on the year, up 6 percent from 2015. Revenue gains were Read More →

Latest

Amgen CEO meets with Trump, vows to add 1,600 jobs

By   /  Tuesday, January 31st, 2017  /  Health Care & Life Science, Latest news  /  Comments Off on Amgen CEO meets with Trump, vows to add 1,600 jobs

Amgen CEO Robert Bradway met with President Donald Trump on Jan. 31 and vowed to add 1,600 jobs, Bloomberg News reported. Trump told biotech leaders at a White House meeting that drug prices needed to come down and he would find a way to streamline the regulatory process. He has discussed having the government negotiate Read More →

Latest

Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira

By   /  Friday, January 27th, 2017  /  Health Care & Life Science, Latest news, Technology  /  Comments Off on Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira

The European Medicines Agency recommended the approval of the ABP 501, a biosimilar of AbbVie’s Humira (adalimumab), for treatment of inflammatory diseases, Thousand Oaks-based biotech company Amgen announced on Jan. 27. The EMA recommended ABP 501’s use for moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis, severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe Read More →